Abstract:Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice's survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine's protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.

The Construction, Bioinformatic Analysis and Vitro Expression of Multi-Epitope Based Gene from Toxoplasma gondii

The construction and characterization of multiple-epitopes vaccine of two new genes of Toxoplasma gondii

Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii.

Epitope Vaccine Design for Toxoplasma Gondii Based on a Genome-Wide Database of Membrane Proteins

Toxoplasma Gondii: Vaccination with a DNA Vaccine Encoding T- and B-cell Epitopes of SAG1, GRA2, GRA7 and ROP16 Elicits Protection Against Acute Toxoplasmosis in Mice

Immunoinformatics studies and design of a novel multi-epitope peptide vaccine against Toxoplasma gondii based on calcium-dependent protein kinases antigens through an in-silico analysis

Toxoplasma Gondii: Bioinformatics Analysis, Cloning and Expression of a Novel Protein TgIMP1

A Toxoplasma Gondii Vaccine Encoding Multistage Antigens in Conjunction with Ubiquitin Confers Protective Immunity to BALB/c Mice Against Parasite Infection

Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis

Construction of Monovalent and Compound Nucleic Acid Vaccines Against Toxoplasma Gondii with Gene Encoding P30

Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis

Evaluation of Protective Effect of Multiantigenic DNA Vaccine Encoding MIC3 and ROP18 Antigen Segments of Toxoplasma Gondii in Mice.

EXPRESSION OF TOXOPLASMA GONDII MULTI-ANTIGENIC GENE ENCODING SAG1 AND ROP1 IN ECOLI

Construction of Eukaryotic Expression Recombinant Plasmid Containing Toxoplasma Gondii GRA2 and Expression in Vitro

Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

Design of a Novel Multi-Epitope Vaccine Against Echinococcus granulosus in Immunoinformatics

Immunoprotection by a Nucleic Acid Vaccine from the GRA1 Gene of Toxoplasma Gondii

Construction of Eimeria Tenella Multi-Epitope DNA Vaccines and Their Protective Efficacies Against Experimental Infection.

Design of a multi-epitope vaccine against goatpox virus using an immunoinformatics approach

Recombinant Expression of Cell Penetrating Peptide TAT Fused with Three Antigens of Toxoplasma Gondii